NOVARTIS

34% of 103 MS patients on ofatumumab experienced end-of-dose phenomena, linked to higher disability, longer disease duration, and older age. Ofatumumab showed lower odds of wearing-off effect vs. ocrelizumab and higher persistence rates compared to other DMTs.

Dato-DXd plus durvalumab achieved a 50% pathologic complete response (pCR) rate in stage II/III high-risk HER2-negative breast cancer patients, according to the I-SPY 2.2 trial. The study emphasizes evaluating treatment response per response predictive subtype (RPS) and suggests further investigation in immune-positive and hormone receptor (HR)-negative/DNA damage repair deficiency (DRD)-negative subtypes. The combination's efficacy was supported by the BEGONIA trial, showing a 79% objective response rate in metastatic triple-negative breast cancer. The I-SPY 2.2 trial design uses RPS to optimize drug assignment, aiming to improve efficacy and minimize toxicity.

The global Personalized Precision Medicine Market report offers detailed segmentation and strategic guidance, covering manufacturers, regions, product categories, and applications. Key insights include market evolution, current conditions, future projections, and analysis of key players like Agilent Technologies, Biogen, Johnson & Johnson, and Novartis. The report aids stakeholders in navigating market dynamics and capitalizing on opportunities.

FDA approves Eli Lilly’s Ebglyss for eczema, Novartis’ Kisqali for early breast cancer, Merck’s Keytruda for malignant pleural mesothelioma, J&J’s Rybrevant for advanced lung cancer, and AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis.

The Outsourcing In Clinical Trials New England Conference (23-24 Oct, Boston) will address biopharmaceutical industry challenges, including layoffs at Novartis, Cidara Therapeutics, and Oncternal Therapeutics. Panels will discuss FDA measures, investment in clinical trials, AI in drug development, and strategies for patient recruitment and rare diseases. Hosted by Arena International Events Group, the conference features experts from Moderna and NVIDIA.

MaxCyte partners with Kamau Therapeutics, Arvato Systems with Advanco, Revance Therapeutics' acquisition impacted by Crown Laboratories, Lifebit and CanPath strategic partnership, Kajeet and Avery Telehealth partnership. FDA approves Apple's sleep apnea detection, Roche's Ocrevus injectable, Novartis Kisqali, Lilly's EBGLYSS, issues alert on Astellas' Veozah, clears Eversense CGM system. Nura Bio raises $68 million, Arzeda $38 million. Cigna's Express Scripts sues FTC, Burson launches Decipher Health, short interest in healthcare stocks rises, Hill Holliday's Quest, Ascendis Pharma's positive Phase 3 results, WHO approves Bavarian Nordic's mpox vaccine, J&J's talc verdict overturned, Prime Therapeutics' new vision, Blue Matter acquires Sam Brown Inc.

Firefly Neuroscience announced advancements in its AI-powered Brain Network Analytics (BNA™) technology, following successful collaborations with Takeda and Novartis. BNA™ aims to accelerate drug development by providing objective measures of brain activity, enhancing trial design, and reducing costs. Firefly plans to expand partnerships with neuroscience pharmaceutical companies.

The global Biotechnology Market is projected to reach USD 6.24 trillion by 2032, driven by R&D investments, healthcare demand, and advancements in pharmaceuticals, agriculture, and environmental management.